Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies
Senescence is a special state of tumor suppression induced by cell cycle arrest. However,
releasing senescence-associated secretory phenotypes by senescent cells could provide …
releasing senescence-associated secretory phenotypes by senescent cells could provide …
[HTML][HTML] Chemoprevention curcumin analog 1.1 promotes metaphase arrest and enhances intracellular reactive oxygen species levels on TNBC MDA-MB-231 and …
D Novitasari, RI Jenie, J Kato… - Research in …, 2023 - journals.lww.com
Background and purpose: Previous studies highlighted that chemoprevention curcumin
analog-1.1 (CCA-1.1) demonstrated an antitumor effect on breast, leukemia, and colorectal …
analog-1.1 (CCA-1.1) demonstrated an antitumor effect on breast, leukemia, and colorectal …
Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment: integrated computational analysis and in vitro study
The treatment of glioblastoma multiforme (GBM) is challenging owing to its localization in the
brain, the limited capacity of brain cells to repair, resistance to conventional therapy, and its …
brain, the limited capacity of brain cells to repair, resistance to conventional therapy, and its …
Preparation and cytotoxic evaluation of PGV-1 derivative, CCA-1.1, as a new curcumin analog with improved-physicochemical and pharmacological properties
Purpose: This study aimed to challenge the anticancer potency of pentagamavunone-1
(PGV-1) and obtain a new compound (Chemoprevention-Curcumin Analog 1.1, CCA-1.1) …
(PGV-1) and obtain a new compound (Chemoprevention-Curcumin Analog 1.1, CCA-1.1) …
[HTML][HTML] CCA-1.1, a novel curcumin analog, exerts cytotoxic anti-migratory activity toward TNBC and HER2-enriched breast cancer cells
Objective: Chemoprevention curcumin Analog-1.1 (CCA-1.1) demonstrates antineoplastic
effect toward cancer cells. By using triple-negative breast cancer (TNBC), 4T1, and human …
effect toward cancer cells. By using triple-negative breast cancer (TNBC), 4T1, and human …
[HTML][HTML] Tumour‐suppressive effects of curcumin analogs CCA‐1.1 and pentagamavunone‐1 in colon cancer: in vivo and in vitro studies
This study aimed to evaluate the efficacy of Chemoprevention Curcumin Analog-1.1 (CCA-
1.1) and Pentagamavunone-1 (PGV-1) in vivo and in vitro in colorectal cancer model. CCA …
1.1) and Pentagamavunone-1 (PGV-1) in vivo and in vitro in colorectal cancer model. CCA …
Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies
D Novitasari, I Nakamae, RI Jenie… - Saudi Pharmaceutical …, 2024 - Elsevier
Abstract Pentagamavunone-1 (PGV-1), an analog of curcumin, has been studied for its
cytotoxic effects in 4T1, MCF7, MCF7/HER2, and T47D breast cancer cells. Its …
cytotoxic effects in 4T1, MCF7, MCF7/HER2, and T47D breast cancer cells. Its …
PGV-1 permanently arrests HepG2 cells in M phase and inhibits liver carcinogenesis in DMH-induced rats
D Novitasari, J Kato, DDP Putri… - Journal of Applied …, 2023 - japsonline.com
Abstract Pentagamavunone-1 (PGV-1) has been reported to eliminate cancer cell
progression in the breast, blood, and colon. The current approach evaluates its …
progression in the breast, blood, and colon. The current approach evaluates its …
A new curcumin analog, CCA-1.1, induces cell death and cell cycle arrest in WiDr colon cancer cells via ROS generation
Abstract The new Pentagamavunone-1 (PGV-1) derivative, chemoprevention-curcumin
analog 1.1 (CCA-1.1), is described as an improved physicochemical feature with similar …
analog 1.1 (CCA-1.1), is described as an improved physicochemical feature with similar …
Africa leaf (Vernonia amygdalina Delille.) DCM extract synergistically supports growth suppression effect of doxorubicin on MCF7 and MCF7/HER2 with different …
Africa leaf (Vernonia amygdalina Delille) has low cytotoxic activities against several cancer
cells. We evaluated its combination treatment with doxorubicin against luminal breast cancer …
cells. We evaluated its combination treatment with doxorubicin against luminal breast cancer …